The news: Half of US pharmaceuticals launched in 2023 underperformed their first-year forecasts, while 39% overperformed, according to an analysis from Trinity Life Sciences.
- Trinity compared the sales performance of new product launches relative to their pre-launch first-year revenue forecasts.